Ron Bose

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. pmc A neu view of invasive lobular breast cancer
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Cancer Res 19:3331-3. 2013
  2. pmc Activating HER2 mutations in HER2 gene amplification negative breast cancer
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Discov 3:224-37. 2013
  3. pmc The ErbB kinase domain: structural perspectives into kinase activation and inhibition
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Exp Cell Res 315:649-58. 2009
  4. pmc Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Shunqiang Li
    Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis, St Louis, MO 63110, USA Siteman Cancer Center Breast Cancer Program, Washington University in St Louis, St Louis, MO 63110, USA
    Cell Rep 4:1116-30. 2013
  5. pmc Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system
    John Monsey
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 285:7035-44. 2010
  6. pmc DGIdb: mining the druggable genome
    Malachi Griffith
    1 The Genome Institute, Washington University School of Medicine, St Louis, Missouri, USA 2 Department of Genetics, Washington University School of Medicine, St Louis, Missouri, USA 3
    Nat Methods 10:1209-10. 2013
  7. pmc Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface
    Timothy S Collier
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 288:25254-64. 2013
  8. pmc HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
    Noa Efrat Ben-Baruch
    From the department of Oncology, Kaplan Medical Center, Rehovot, Israel Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, and Washington University School of Medicine, St Louis, Missouri and Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
    J Natl Compr Canc Netw 13:1061-4. 2015
  9. pmc HER2 activating mutations are targets for colorectal cancer treatment
    Shyam M Kavuri
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
    Cancer Discov 5:832-41. 2015
  10. pmc Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers
    Alaina P Boyer
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Mol Cell Proteomics 12:180-93. 2013

Collaborators

Detail Information

Publications19

  1. pmc A neu view of invasive lobular breast cancer
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Cancer Res 19:3331-3. 2013
    ..HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain...
  2. pmc Activating HER2 mutations in HER2 gene amplification negative breast cancer
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Discov 3:224-37. 2013
    ..These findings show that HER2 somatic mutation is an alternative mechanism to activate HER2 in breast cancer and they validate HER2 somatic mutations as drug targets for breast cancer treatment...
  3. pmc The ErbB kinase domain: structural perspectives into kinase activation and inhibition
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Exp Cell Res 315:649-58. 2009
    ..We will review these regulation mechanisms of the ErbB kinase domain, and discuss the binding specificity of kinase inhibitors and the effects of kinase domain mutations found in cancer patients from a structural perspective...
  4. pmc Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Shunqiang Li
    Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis, St Louis, MO 63110, USA Siteman Cancer Center Breast Cancer Program, Washington University in St Louis, St Louis, MO 63110, USA
    Cell Rep 4:1116-30. 2013
    ..The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation. ..
  5. pmc Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system
    John Monsey
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 285:7035-44. 2010
    ....
  6. pmc DGIdb: mining the druggable genome
    Malachi Griffith
    1 The Genome Institute, Washington University School of Medicine, St Louis, Missouri, USA 2 Department of Genetics, Washington University School of Medicine, St Louis, Missouri, USA 3
    Nat Methods 10:1209-10. 2013
    ..It provides an interface for searching lists of genes against a compendium of drug-gene interactions and potentially 'druggable' genes. DGIdb can be accessed at http://dgidb.org/. ..
  7. pmc Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface
    Timothy S Collier
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 288:25254-64. 2013
    ..This study provides valuable insights into the EGF receptor/HER/ErbB kinase structure and interactions, which can guide the design of future therapies. ..
  8. pmc HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
    Noa Efrat Ben-Baruch
    From the department of Oncology, Kaplan Medical Center, Rehovot, Israel Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, and Washington University School of Medicine, St Louis, Missouri and Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
    J Natl Compr Canc Netw 13:1061-4. 2015
    ....
  9. pmc HER2 activating mutations are targets for colorectal cancer treatment
    Shyam M Kavuri
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
    Cancer Discov 5:832-41. 2015
    ..Treatment with a single HER2-targeted drug (trastuzumab, neratinib, or lapatinib) delayed tumor growth, but dual HER2-targeted therapy with trastuzumab plus tyrosine kinase inhibitors produced regression of these HER2-mutated PDXs...
  10. pmc Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers
    Alaina P Boyer
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Mol Cell Proteomics 12:180-93. 2013
    ..These proteins may present targets for the development of clinical diagnostics or therapeutic strategies to guide the treatment of HER2+ breast cancer patients who develop trastuzumab resistance...
  11. pmc Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase
    Hao Zhang
    Department of Chemistry, Washington University, St Louis, MO 63130, USA
    Mol Cell Proteomics 10:M110.005678. 2011
    ..5-6.8 × 10(12) dm(2)/mol). This suggests that the kinase-domain makes a significant contribution to the overall dimerization affinity of the full-length Her4 protein...
  12. pmc Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data
    Runjun D Kumar
    Division of Oncology, Department of Medicine, Washington University School of Medicine, Computational and Systems Biology Program, Washington University in St Louis
    Bioinformatics 31:3561-8. 2015
    ..A method which accounts for these subclasses could improve performance while also suggesting a mechanism of action for new putative cancer genes...
  13. doi request reprint Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer
    Cynthia X Ma
    Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, 63110, St Louis, MO, USA
    Adv Exp Med Biol 882:125-54. 2016
    ..The recognition of somatic mutations and their relationship to endocrine therapy responsiveness opens important opportunities toward this goal. ..
  14. doi request reprint Incorporating genomics into breast cancer clinical trials and care
    Adel Tabchy
    Authors Affiliation Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
    Clin Cancer Res 19:6371-9. 2013
    ....
  15. pmc Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer
    Adam C Searleman
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Electrophoresis 35:3463-9. 2014
    ..These results demonstrate that PolyMAC is well suited for phosphoproteomic analysis of tissue specimens. ..
  16. ncbi request reprint Using multigene tests to select treatment for early-stage breast cancer
    Rodrigo Gonçalves
    Division of Oncology, Department of Medicine, Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, St Louis, MO 63110, USA
    J Natl Compr Canc Netw 11:174-82; quiz 182. 2013
    ....
  17. pmc Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J Ellis
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
    Nature 486:353-60. 2012
    ..Prospective clinical trials based on these findings will require comprehensive genome sequencing...
  18. pmc Genomic landscape of non-small cell lung cancer in smokers and never-smokers
    Ramaswamy Govindan
    Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Cell 150:1121-34. 2012
    ..Cell-cycle and JAK-STAT pathways are significantly altered in lung cancer, along with perturbations in 54 genes that are potentially targetable with currently available drugs...